Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




A Rapid, Non-Invasive Skin Test for Diagnosis of Parkinson’s Disease

By LabMedica International staff writers
Posted on 22 Mar 2021
A team of British investigators has developed a rapid, non-invasive method for identifying Parkinson's disease based on compounds found on the surface of skin.

The test developed by investigators at the University of Manchester (United Kingdom) was the product of previously published studies showing that volatile compounds on skin could be used to diagnose Parkinson's disease (PD). More...
The compounds were localized to the sebum, which is secreted by the sebaceous glands in the skin. It is primarily composed of triglycerides (approximately 41%), wax esters (approximately 26%), squalene (approximately 12%), and free fatty acids (approximately 16%). Wax esters and squalene are unique to sebum and not produced as final products anywhere else in the body. Sapienic acid is a sebum fatty acid that is unique to humans, and is implicated in the development of acne. Sebum is odorless, but its breakdown by bacteria can produce strong odors.

For the current study, the investigators used liquid chromatography-mass spectrometry (LC-MS) to analyze 274 sebum samples taken with swabs from the upper backs of participants (80 drug naïve PD, 138 medicated PD, and 56 well matched control subjects) in order to detect metabolites that could predict the PD phenotype. Result revealed that LC-MS identified10 chemical compounds in sebum, which were elevated or reduced in PD patients. Pathway enrichment analysis indicated that there were alterations in lipid metabolism related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism, and fatty acid biosynthesis.

Senior author Dr. Perdita Barran, professor of mass spectrometry at the University of Manchester, said, "We believe that our results are an extremely encouraging step towards tests that could be used to help diagnose and monitor Parkinson's. Not only is the test quick, simple, and painless but it should also be extremely cost-effective because it uses existing technology that is already widely available. We are now looking to take our findings forwards to refine the test to improve accuracy even further and to take steps towards making this a test that can be used in the NHS (National Health Service) and to develop more precise diagnostics and better treatment for this debilitating condition."

The sebum analysis method was described in the March 11, 2021, online edition of the journal Nature Communications.

Related Links:
University of Manchester


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.